Akero Therapeutics, Inc. (AKRO) DCF Valuation

Akero Therapeutics, Inc. (AKRO) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Akero Therapeutics, Inc. (AKRO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Enhance your investment choices with the Akero Therapeutics, Inc. (AKRO) DCF Calculator! Explore actual Apple financial data, adjust growth predictions and expenses, and instantly observe how these modifications affect the intrinsic value of Akero Therapeutics, Inc. (AKRO).


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -45.7 -79.0 -100.5 -111.0 -148.6 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation -.1 .2 .2 .3 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -45.5 -79.2 -100.8 -111.3 -148.7 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 136.4 268.4 188.3 351.4 550.0 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .9 3.4 6.7 8.0 7.0 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 -.1 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -45.5 -79.2 -100.7 -108.2 -148.7 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -44.7 -76.6 -97.2 -106.7 -149.6 -7.0 .0 .0 .0 .0
WACC, % 5.51 5.51 5.51 5.5 5.51 5.5 5.5 5.5 5.5 5.5
PV UFCF
SUM PV UFCF -6.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -7
Net Debt -208
Equity Value 201
Diluted Shares Outstanding, MM 53
Equity Value Per Share 3.83

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
  • Real-World Data: Akero Therapeutics’ financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
  • Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.

Key Features

  • Comprehensive Financial Data: Gain access to precise pre-loaded historical data and future forecasts for Akero Therapeutics, Inc. (AKRO).
  • Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
  • User-Friendly Dashboard: Intuitive charts and summaries to help visualize valuation outcomes.
  • Suitable for All Levels: Designed with a straightforward structure for investors, CFOs, and consultants alike.

How It Works

  • 1. Download the Model: Obtain and open the Excel template featuring Akero Therapeutics, Inc.'s (AKRO) financial data.
  • 2. Adjust Key Variables: Modify critical inputs such as revenue growth rates, discount rates, and research & development expenses.
  • 3. Analyze Results in Real-Time: The DCF model automatically computes the intrinsic value and net present value (NPV).
  • 4. Explore Different Scenarios: Evaluate various projections to understand potential valuation impacts.
  • 5. Present with Assurance: Deliver expert valuation analyses to enhance your strategic decisions.

Why Choose This Calculator for Akero Therapeutics, Inc. (AKRO)?

  • User-Friendly Interface: Tailored for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters easily to suit your financial analysis.
  • Real-Time Adjustments: Observe immediate updates to Akero's valuation as you change inputs.
  • Pre-Loaded Data: Comes with Akero’s latest financial metrics for swift evaluations.
  • Relied Upon by Experts: Favored by investors and analysts for making strategic decisions.

Who Should Use This Product?

  • Biotech Students: Understand drug development processes and apply your knowledge using real-world data.
  • Researchers: Integrate advanced therapeutic models into your studies or publications.
  • Investors: Validate your investment hypotheses and evaluate market performance for Akero Therapeutics, Inc. (AKRO).
  • Market Analysts: Enhance your analysis with a comprehensive, customizable financial model tailored for biotech firms.
  • Healthcare Entrepreneurs: Discover how leading biotech companies like Akero Therapeutics are evaluated and positioned in the market.

What the Template Contains

  • Pre-Filled DCF Model: Akero Therapeutics’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Akero Therapeutics’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.